Evidence map›Paper›PMID 41652233›Full record

ArticleVirchows Archiv : an international journal of pathology2026

Evaluation of homologous recombination testing in ovarian carcinoma.

Vera M Witjes, Joanne A de Hullu, Angela van Remortele, Lilian Vreede, Efraim H Rosenberg, Saskia A G M Cillessen, Floris H Groenendijk, Elisabeth M P Steeghs, Laura Moonen, Arjen R Mensenkamp and 4 more

Abstract readEvaluation StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Vera M WitjesDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Joanne A de HulluResearch Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
Angela van RemorteleDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Lilian VreedeDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Efraim H RosenbergDepartment of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Saskia A G M CillessenDepartment of Pathology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Floris H GroenendijkDepartment of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
Elisabeth M P SteeghsDepartment of Pathology, Leiden University Medical Center, Leiden, the Netherlands.
Laura MoonenDepartment of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands.
Arjen R MensenkampDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Arja Ter ElstDepartment of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Wendy W J de LengDepartment of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands.
Nicoline HoogerbruggeDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands.
Marjolijn J L LigtenbergDepartment of Human Genetics, Radboud University Medical Center, Nijmegen, the Netherlands. Marjolijn.Ligtenberg@radboudumc.nl.ORCID http://orcid.org/0000-0003-1290-1474

Funding

KWF Kankerbestrijding 12732
6 · The paper itself

Abstract

Homologous recombination deficiency (HRD) testing may be used to stratify ovarian carcinoma (OC) patients for PARP inhibitor therapy. In the Netherlands, different NGS-based assays are used to assess genomic instability as a hallmark of HRD. We evaluated the uniformity of HRD testing. Firstly, interlaboratory assessments of 10 tumors were performed in 8 centers. 71 out of the 77 (92%) successful tests were concordant. Results were more consistent in OC with a pathogenic variation (PV) or promoter methylation of a homologous recombination repair (HRR) gene (97%) than in those without (87%). Secondly, concordance between BRCA1/RAD51C promoter methylation and HRD was assessed in 244 samples without a PV in HRR genes. BRCA1/RAD51C promoter methylation was present in 38 out of 100 (38%) samples classified as HRD, and absent in all (n = 144) non-HRD samples (p < 0.001). Lastly, pathology reports from 765 HRD tests were reviewed to evaluate routine diagnostics. Testing was successful in 695 (91%) cases. HRD detection rates were higher in high-grade serous OC compared to other histological subtypes (49% versus 12%, p < 0.001). The five HRD assays varied significantly in HRD detection rates in high-grade serous OC. The results support the applicability of genomic instability analyses to assess HRD, while also highlighting the need to improve harmonization across different assays when HRD is used for therapeutic decision making.

Indexed as

Homologous RecombinationOvarian NeoplasmsRecombinational DNA RepairBRCA1 ProteinDNA-Binding ProteinsDNA MethylationFemaleGenomic InstabilityHumansMiddle AgedPoly(ADP-ribose) Polymerase InhibitorsPromoter Regions, GeneticBRCA1 ProteinBRCA1 protein, humanDNA-Binding ProteinsPoly(ADP-ribose) Polymerase InhibitorsRAD51C protein, humanBRCAGenomic instabilityHomologous recombination deficiencyOvarian cancerPARP inhibitorsQuality control

Identifiers

PMID41652233
PMCPMC13053547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.